Civorebrutinib is an investigational candidate for the treatment of several immune-mediated rare kidney diseases
Civorebrutinib is an investigational covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in development for rare immune-mediated kidney diseases. These include immune-mediated focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), primary membranous nephropathy (pMN) and potentially other indications. In 2026, Travere Therapeutics entered into an exclusive licensing and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib in the U.S. and markets outside China and certain countries in East and Southeast Asia.1
In immune-mediated FSGS, MCD, and pMN, the body’s immune system can damage the kidney’s filtering units (nephrons). This damage often results in nephrotic syndrome, proteinuria, and progressive loss of kidney function, which can lead to kidney failure requiring transplant or dialysis. There is a significant unmet need for targeted therapies in immune-mediated rare kidney conditions that provide effective disease control while minimizing treatment burden.
Civorebrutinib is designed to selectively and reversibly inhibit BTK, a key regulator of B-cell activation and an important part of the immune response, in immune-mediated kidney disease. The goal of the civorebrutinib program is to develop a well-tolerated, safe and effective medicine that provides targeted immune modulation to reduce proteinuria across multiple immune-mediated kidney diseases.
Civorebrutinib is currently being evaluated by Everest Medicines in an ongoing Phase 1b/2a clinical study in people with anti-PLA2R antibody-positive primary membranous nephropathy (pMN), which accounts for approximately 70–80% of pMN cases.2 Results reported to date have demonstrated rapid and sustained reductions in anti-PLA2R antibodies and proteinuria, and a generally well-tolerated safety profile. Everest Medicines has also initiated an exploratory Phase 2 basket study evaluating civorebrutinib in immune-mediated FSGS, MCD and IgA nephropathy.
Civorebrutinib is an investigational therapy that has not been approved by the FDA or any other regulatory authority.